Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes

Metabolism: Clinical and Experimental

Volumn 53, Issue 3, 2004, Pages 297-302

  Tsuzura, Sachie ^a   Ikeda, Yukio ^a   Suehiro, Tadashi ^a   Ota, Kikuko ^a   Osaki, Fumiaki ^a   Arii, Kaoru ^a   Kumon, Yoshitaka ^a   Hashimoto, Kozo ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; OXIDIZED LOW DENSITY LIPOPROTEIN; STATINE DERIVATIVE; ARYLESTERASE; CARBOXYLESTERASE; CHOLESTEROL; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC ANGIOPATHY; DNA POLYMORPHISM; ENZYME ACTIVITY; FEMALE; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; IN VIVO STUDY; JAPAN; LIPID BLOOD LEVEL; LIPID PEROXIDATION; MALE; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROMOTER REGION; BLOOD; CLINICAL TRIAL; DIABETIC NEPHROPATHY; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; AGED; APOLIPOPROTEINS B; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE STRESS; POLYMORPHISM, GENETIC; TRIGLYCERIDES;

EID: 1842454052     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2003.10.009     Document Type: Article

References (31)

1. Navab M, Berliner JA, Watson AD, et al: The yin and yang of oxidation in the development of the fatty streak: A review based on the 1994 George Lyman Duff memorial lecture. Arterioscler Thromb Vasc Biol 16:831-842, 1996
2. Witzum JL: The oxidation hypothesis of atherosclerosis. Lancet 344:793-795, 1994
3. Berliner JA, Heinecke JW: The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 20:707-727, 1996
4. Steinberg D: Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 272:20963-20966, 1997
5. Blatter MC, James RW, Messmer S, et al: Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45: Identity of K-45 with paraoxonase. Eur J Biochem 211:871-879, 1993
6. Mackness MI, Arrol S, Durrington PN: Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 286:152-154, 1991
7. Mackness MI, Arrol S, Abbott C, et al: Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 104:129-135, 1993
8. Adkins S, Gan KN, Mody M, et al: Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: Glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 52:598-608, 1993
9. Humbert R, Adler DA, Disteche CM, et al: The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 3:73-76, 1993
10. Garin MC, James RW, Dussoix P, et al: Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme: A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 99:62-66, 1997
11. Leviev I, Negro F, James RW: Two alleles of the human paraoxonase gene produce different amounts of mRNA: An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler Thromb Vasc Biol 17:2935-2939, 1997
12. Mackness B, Mackness MI, Arrol S, et al: Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 139:341-349, 1998
13. Brophy VH, Jarvik GP, Richter RJ, et al: Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype. Pharmacogenetics 10:453-460, 2000
14. Suehiro T, Nakamura T, Inoue M, et al: A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis 150:295-298, 2000
15. Leviev I, James RW: Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 20:516-521, 2000
16. Brophy VH, Hastings MD, Clendenning JB, et al: Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 11:77-84, 2001
17. Wolff SP, Jiang ZY, Hunt JV: Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic Biol Med 10:339-352, 1991
18. Nourooz-Zadeh J, Tajaddini-Sarmadi J, McCarthy S, et al: Elevated levels of authentic plasma hydroperoxides in NIDDM. Diabetes 44:1054-1058, 1995
19. Ikeda Y, Suehiro T, Inoue M, et al: Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus. Metabolism 47:598-602, 1998
20. Abbott CA, Mackness MI, Kumar S, et al: Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 15:1812-1818, 1995
21. World Health Organization, Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Part 1: Diagnosis and Classification of diabetes mellitus, Report of a WHO Consultation, Geneva, World Health Org, 1999
22. Holvoet P, Vanhaecke J, Janssens S, et al: Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 98:1487-1494, 1998
23. de Graaf J, Hak-Lemmers HL, Hectors MP, et al: Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subtraction in healthy subjects. Arterioscler Thromb 11:298-306, 1991
24. Hurt-Camejo E, Camejo G, Rosengren B, et al: Effect of arterial proteoglycans and glycosaminoglycans on low density lipoprotein oxidation and its uptake by human macrophages and arterial smooth muscle cells. Arterioscler Thromb 12:569-583, 1992
25. Kondo A, Muranaka Y, Ohta I, et al: Relationship between triglyceride concentrations and LDL size evaluated by malondialdehyde-modified LDL. Clin Chem 47:893-900, 2001
26. Ross R: The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362:801-809, 1993
27. Berliner JA, Navab M, Fogelman AM, et al: Atherosclerosis: Basic mechanisms: Oxidation, inflammation, and genetics. Circulation 91:2488-2496, 1995
28. Barter PJ, Rye KA: Molecular mechanisms of reverse cholesterol transport. Curr Opin Lipidol 7:82-87, 1996
29. Hedrick CC, Thorpe SR, Fu M-X, et al: Glycation impairs high-density lipoprotein function. Diabetologia 43:312-320, 2000
30. Aviram M, Billecke S, Sorenson R, et al: Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: Selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 18:1617-1624, 1998
31. Cao H, Girard-Globa A, Berthezene F, et al: Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q→R genetic polymorphism. J Lipid Res 40:133-139, 1999